Pluristem Therapeutics is developing a new therapy that could prolong survival and improve the quality of life for patients with damaged hematological systems.
Prof. Reuven Or, from the Bone Marrow Transplantation and Cancer Immunotherapy Research Center, speaks with Pluristem CEO Zami Aberman last month.(photo credit: PLURISTEM)ByMAAYAN HOFFMANUpdated:
